Sarcopenia in Gestational Diabetes (SiGnal-D)

Istituto di Neuroscienze Consiglio Nazionale delle Ricerche

Status

Enrolling

Conditions

Cognitive Function

Pregnancy Complications

Gestational Diabetes Mellitus (GDM)

Sarcopenia

Adverse Maternal and Neonatal Outcomes

Treatments

Other: Montreal Cognitive Assessment

Diagnostic Test: Oral Glucose Tolerance Test

Diagnostic Test: Sarcopenia tests (for muscle mass, muscle function, physical performance)

Study type

Observational

Funder types

Other

NETWORK

Identifiers

NCT06876090

2022XYXRJN_LS4_PRIN2022

B53D23022000006 (Other Grant/Funding Number)

Details and patient eligibility

About

Sarcopenia is a syndrome characterized by loss of skeletal muscle mass and strength, and physical performance deterioration. Prevalence of sarcopenia in elderly people is remarkably high (prevalence of about 25% in 60+ years people). In type 2 diabetes (T2D), sarcopenia is emerging as comorbidity of major concern. Sarcopenia, however, is not limited to elderly people, as it can develop also in younger individuals with prevalence around 9% or even higher according to some investigators. Of note, sarcopenia has been reported even in the 20-29 years interval. This interval includes women of childbearing age, thus raising the question whether sarcopenia may occur also in women with gestational diabetes (GDM) and whether this may affect pregnancy outcomes. Also, association between sarcopenia and cognitive impairment has been repeatedly reported, to the point that some authors have emphasized the importance of early sarcopenia recognition for prevention of cognitive impairment. Therefore, our main aims are:

To ascertain whether sarcopenia is present in GDM and, in that case, its prevalence;
To identify risk factors for sarcopenia;
To determine sarcopenia impact on pregnancy outcomes, and cognitive function.

During pregnancy, all women will undergo oral glucose tolerance test (OGTT) for assessment of the glucometabolic condition. Several clinical variables of interest in sarcopenia will also be recorded. As regards the OGTT data, special focus will be on the assessment of insulin resistance, both at fasting and during the dynamic conditions determined by the OGTT. Notably, the special interest for insulin resistance is due to the reason that this type of metabolic alteration is known to be a risk factor for sarcopenia. In fact, all women will then undergo testing for diagnosis of sarcopenia (or presarcopenia), and all data and parameters will be analyzed to identify relationships between sarcopenia-related variables and GDM-related ones. It is worth noting that in consideration of the exacerbated insulin resistance condition often observed in GDM, the investigators expect indeed a not negligible prevalence of sarcopenia (or at least presarcopenia) in GDM women, despite the young (non-elderly) age. In addition, since insulin resistance is often present in pregnancy even in the absence of dysglycemia, the investigators do not exclude to identify some cases of sarcopenia/presarcopenia even in pregnant non-GDM women. This study will be the basis for future studies (also of interventional type), especially in women with GDM for prevention of sarcopenia and related possible pregnancy complication and adverse pregnancy outcomes, as well as for possibly contributing to mitigation of risk for T2D development in later life.

Enrollment

200 estimated patients

Sex

Female

Ages

35+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

At least one among the following conditions:

Age equal to or higher than 35 years;
Body mass index (BMI) equal to or higher than 25 kg/m^2;
Glycemia between 5.6 and 6.9 mmol/L before or at the beginning of pregnancy;
Fetal macrosomia in previous pregnancy;
GDM in previous pregnancy;
First-degree family history of diabetes.

Exclusion criteria

Unmatching of at least one among the inclusion criteria;
Twin pregnancy;
Presence of any already known disease/disorder possibly affecting muscle mass or function;
Neurological or psychiatric diseases;
Already known diabetes (e.g., type 1 or type 2 diabetes).